Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/137534
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhang, Y.-L. | - |
dc.contributor.author | Liu, L. | - |
dc.contributor.author | Su, Y.-W. | - |
dc.contributor.author | Xian, C.J. | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | International Journal of Molecular Sciences, 2021; 22(20):1-19 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.uri | https://hdl.handle.net/2440/137534 | - |
dc.description.abstract | Intensive methotrexate (MTX) treatment for childhood malignancies decreases osteogenesis but increases adipogenesis from the bone marrow stromal cells (BMSCs), resulting in bone loss and bone marrow adiposity. However, the underlying mechanisms are unclear. While microRNAs (miRNAs) have emerged as bone homeostasis regulators and miR-542-3p was recently shown to regulate osteogenesis in a bone loss context, the role of miR-542-3p in regulating osteogenesis and adipogenesis balance is not clear. Herein, in a rat MTX treatment-induced bone loss model, miR542-3p was found significantly downregulated during the period of bone loss and marrow adiposity. Following target prediction, network construction, and functional annotation/ enrichment analyses, luciferase assays confirmed sFRP-1 and Smurf2 as the direct targets of miR-542-3p. miRNA-542-3p overexpression suppressed sFRP-1 and Smurf2 expression post-transcriptionally. Using in vitro models, miR-542-3p treatment stimulated osteogenesis but attenuated adipogenesis following MTX treatment. Subsequent signalling analyses revealed that miR-542-3p influences Wnt/β-catenin and TGF-β signalling pathways in osteoblastic cells. Our findings suggest that MTX treatment-induced bone loss and marrow adiposity could be molecularly linked to miR-542-3p pathways. Our results also indicate that miR-542-3p might be a therapeutic target for preserving bone and attenuating marrow fat formation during/after MTX chemotherapy. | - |
dc.description.statementofresponsibility | Ya-Li Zhang, Liang Liu, Yu-Wen Su and Cory J. Xian | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.rights | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). | - |
dc.source.uri | http://dx.doi.org/10.3390/ijms222010988 | - |
dc.subject | methotrexate; miRNA-542-3p; bone formation; marrow adiposity | - |
dc.subject.mesh | Bone and Bones | - |
dc.subject.mesh | Cell Line | - |
dc.subject.mesh | Animals | - |
dc.subject.mesh | Mice | - |
dc.subject.mesh | Rats | - |
dc.subject.mesh | Rats, Sprague-Dawley | - |
dc.subject.mesh | Methotrexate | - |
dc.subject.mesh | Ubiquitin-Protein Ligases | - |
dc.subject.mesh | Intercellular Signaling Peptides and Proteins | - |
dc.subject.mesh | Membrane Proteins | - |
dc.subject.mesh | MicroRNAs | - |
dc.subject.mesh | 3' Untranslated Regions | - |
dc.subject.mesh | Cell Differentiation | - |
dc.subject.mesh | Down-Regulation | - |
dc.subject.mesh | Osteogenesis | - |
dc.subject.mesh | Models, Biological | - |
dc.subject.mesh | Female | - |
dc.subject.mesh | Male | - |
dc.subject.mesh | Adipogenesis | - |
dc.subject.mesh | Wnt Signaling Pathway | - |
dc.subject.mesh | Antagomirs | - |
dc.title | miR-542-3p Attenuates Bone Loss and Marrow Adiposity Following Methotrexate Treatment by Targeting sFRP-1 and Smurf2 | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.3390/ijms222010988 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Zhang, Y.-L. [0000-0003-0107-4274] | - |
Appears in Collections: | Chemical Engineering publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_137534.pdf | Published version | 34.75 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.